| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K02251932 | CTRPv2 | pan-cancer | AAC | -0.0089 | 0.8 |
| mRNA | BRD-K27188169:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.012 | 0.8 |
| mRNA | BCL-LZH-4 | CTRPv2 | pan-cancer | AAC | 0.012 | 0.8 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | -0.0064 | 0.8 |
| mRNA | Elesclomol | GDSC1000 | pan-cancer | AAC | -0.0072 | 0.8 |
| mRNA | BRD-K34485477 | CTRPv2 | pan-cancer | AAC | -0.016 | 0.8 |
| mRNA | SB-431542 | CTRPv2 | pan-cancer | AAC | -0.0079 | 0.8 |
| mRNA | NSC95397 | CTRPv2 | pan-cancer | AAC | 0.0068 | 0.8 |
| mRNA | tacrolimus | CTRPv2 | pan-cancer | AAC | 0.0071 | 0.8 |
| mRNA | ML312 | CTRPv2 | pan-cancer | AAC | -0.015 | 0.8 |